<!doctype html>
<html>
  <head>
    <title>Pharm Table</title>
    <meta http-equiv="Content-type" content="text/html;charset=UTF-8" />

    <style>
      body {
        font-family:
          -apple-system, BlinkMacSystemFont, "Segoe WPC", "Segoe UI", "Ubuntu",
          "Droid Sans", sans-serif, "Meiryo";
        padding: 0 12px;
      }

      table {
        border-collapse: collapse;
        margin-bottom: 24px;
        width: 100%;
      }
      table > thead > tr > th,
      table > tbody > tr > td {
        padding: 5px 10px;
      }
      table > thead > tr > th {
        text-align: left;
        border-bottom: 1px solid;
      }
      table > tbody > tr + tr > td {
        border-top: 1px solid;
      }

      .tooltip {
        position: relative;
        cursor: pointer;
        display: inline-block;
      }
      .tooltip img {
        display: none;
        position: absolute;
        width: var(--tooltip-img-width, 300px);
        height: auto;
        border: 2px solid #f00;
        background: #ffffcc;
        padding: 5px;
        z-index: 10;
        bottom: 100%;
        left: 50%;
        transform: translateX(10px);
        max-width: 90vw; /* ✅ prevents image from exceeding viewport width */
        max-height: 80vh; /* ✅ keeps image inside visible page vertically */
        object-fit: contain;
        box-sizing: border-box;
      }

      .tooltip[data-position="below"] img {
        bottom: auto;
        top: 100%;
      }

      .tooltip:hover img {
        display: block;
        /* Reposition if too close to top or bottom of viewport */
        top: auto;
        bottom: auto;
      }

      .blurred {
        filter: blur(3px);
        transition: filter 0.3s ease;
      }

      table td:not(:first-child),
      table td li {
        cursor: pointer;
      }

      summary {
        font-size: 22px;
        font-weight: bold;
        cursor: pointer;
        margin: 16px 0;
      }

      details {
        border: 2px solid #444;
        border-radius: 8px;
        padding: 10px;
        background: #f9f9f9;
      }
    </style>
  </head>
  <body>
    <h2>Protected Content</h2>
    <p>Please enter the password to view the content:</p>
    <input type="password" id="password" placeholder="Enter password" />
    <button onclick="checkPassword()">Submit</button>
    <div id="content" style="display: none; margin-top: 20px">
      <!-- <div> -->
      <div class="blur-buttons">
        <button id="blurAll">Blur All</button>
        <button id="unblurAll">Unblur All</button>
      </div>
      <!-- Center a div -->
      <div style="display: flex; justify-content: center; align-items: center">
        Nathan Hoang's Pharm Table
      </div>
      <br />
      <!-- Lecture 3 -->
      <details>
        <summary>Lecture 3: Local Anesthetics</summary>
        <my-header>Ester Local Anesthetics</my-header>
        <table>
          <thead>
            <tr>
              <th>Drug</th>
              <th>Class</th>
              <th>Onset</th>
              <th>Duration</th>
              <th>Metabolism / Notes</th>
              <th>Max dose (per appointment)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>Benzocaine</strong> (topical)</td>
              <td>Ester (topical)</td>
              <td>Topical, rapid</td>
              <td>&mdash;</td>
              <td>
                <ul>
                  <li>Ester metabolized by plasma pseudocholinesterase</li>
                  <li>
                    Low systemic absorption in topical gels (20% benzocaine
                    examples)
                  </li>
                </ul>
              </td>
              <td>&mdash; [topical product doses vary]</td>
            </tr>
            <tr>
              <td><strong>Procaine (Novocain&reg;)</strong></td>
              <td>Ester</td>
              <td>6–10 min</td>
              <td>15–60 min</td>
              <td>
                <ul>
                  <li>Ester (pseudocholinesterase metabolism)</li>
                  <li>Significant vasodilation</li>
                  <li>Highly allergenic (PABA)</li>
                </ul>
              </td>
              <td>&mdash;</td>
            </tr>
            <tr>
              <td><strong>Chloroprocaine (Nesacaine&reg;)</strong></td>
              <td>Ester</td>
              <td>5–15 min</td>
              <td>30–90 min</td>
              <td>
                <ul>
                  <li>Rapidly metabolized by plasma esterases</li>
                  <li>Used epidurally (e.g., obstetrics)</li>
                  <li>Used for pregnancy to manage delivery</li>
                </ul>
              </td>
              <td>&mdash;</td>
            </tr>
            <tr>
              <td><strong>Tetracaine</strong></td>
              <td>Ester</td>
              <td>Short onset</td>
              <td>Longer duration (high potency)</td>
              <td>
                Ester class (plasma metabolism, PABA risk) &mdash; often used in
                spinal anesthesia
              </td>
              <td>&mdash;</td>
            </tr>
          </tbody>
        </table>
        <my-header>Amide Local Anesthetics</my-header>
        <table>
          <thead>
            <tr>
              <th>Drug</th>
              <th>Class</th>
              <th>Onset</th>
              <th>Duration</th>
              <th>Metabolism / Notes</th>
              <th>Max dose (per appointment)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>Lidocaine</strong></td>
              <td>Amide</td>
              <td>3–5 min</td>
              <td>Moderate (prolonged with epinephrine)</td>
              <td>
                <ul>
                  <li>Metabolized in liver by microsomal CYP‑450</li>
                  <li>Active metabolites M.E.G.X. and G.X.</li>
                  <li>
                    Vasodilator (use with epinephrine), so risk of bleeding
                  </li>
                  <li>
                    2% lidocaine used with epinephrine as a vasoconstrictor
                  </li>
                </ul>
              </td>
              <td>500 mg</td>
            </tr>
            <tr>
              <td><strong>Mepivacaine</strong></td>
              <td>Amide</td>
              <td>3–5 min</td>
              <td>Short (~20 min without vasoconstrictor)</td>
              <td>
                <ul>
                  <li>Metabolized in liver by CYP‑450 (like lidocaine)</li>
                  <li>
                    Slight intrinsic vasoconstriction — may be used without
                    epinephrine
                  </li>
                </ul>
              </td>
              <td>400 mg</td>
            </tr>
            <tr>
              <td><strong>Prilocaine Hydrochloride (Citanest&reg;)</strong></td>
              <td>Amide</td>
              <td>3–5 min</td>
              <td>10 min (no vasoconstrictor) → up to ~90 min (with VC)</td>
              <td>
                <ul>
                  <li>Metabolized in liver and kidneys via amidases</li>
                  <li>
                    Produces ortho‑toluidine (risk of methemoglobinemia, esp.
                    G6PD)
                  </li>
                  <li>Hepatic and renal dysfunction can alter its kinetics</li>
                  <strong>Precautions:</strong>
                  <ul>
                    <li>
                      Metabolized in both liver and kidney and small degree in
                      lungs yielding various metabolites
                    </li>
                    <li>
                      Ortho-toluidine may cause methemoglobinemia (especially in
                      G6PD deficiency)
                    </li>
                  </ul>
                </ul>
              </td>
              <td>600 mg</td>
            </tr>
            <tr>
              <td><strong>Articaine (Septocaine&reg;)</strong></td>
              <td>Amide (contains ester group)</td>
              <td>1–6 min</td>
              <td>
                <ul>
                  <li>Moderate</li>
                  <li>Rapid clearance (t&frac12; &approx; 20 min)</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    Metabolized mainly in blood by plasma carboxyesterase and to
                    lesser extent in liver (CYP) &mdash; suitable in renal
                    dysfunction
                  </li>
                  <li>Contains both ester &amp; amide moieties</li>
                  <li>Suitable for patients with renal dysfunction</li>
                </ul>
              </td>
              <td>No absolute max (limited by epinephrine)</td>
            </tr>
            <tr>
              <td><strong>Bupivacaine (Marcaine&reg;)</strong></td>
              <td>Amide</td>
              <td>2–10 min</td>
              <td>Long (&approx; 90–180 min)</td>
              <td>
                <ul>
                  <li>
                    Metabolized in liver by amidases to inactive metabolites
                  </li>
                  <li>
                    High vasodilator activity (often paired with epinephrine)
                  </li>
                </ul>
              </td>
              <td>90 mg</td>
            </tr>
          </tbody>
        </table>
      </details>
      <br />
      <!-- Lecture 4 -->
      <details>
        <summary>Lecture 4: Management of Psychiatric Disorders</summary>
        <table>
          <thead>
            <tr>
              <th><strong>Drug</strong></th>
              <th><strong>Class / Group</strong></th>
              <th><strong>Indication</strong></th>
              <th><strong>MOA</strong></th>
              <th><strong>Adverse effects / Interactions</strong></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>Levodopa–Carbidopa (Sinemet®)</strong></td>
              <td>Anti‑Parkinson (dopamine precursor)</td>
              <td>Parkinson disease</td>
              <td>
                <ul>
                  <li>Levodopa converted to dopamine in CNS</li>
                  <li>
                    Carbidopa inhibits peripheral decarboxylase to increase CNS
                    availability, by inhibiting metabolism of levodopa
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Orthostatic hypotension</li>
                  <li>
                    <b> Hallucinations </b>
                  </li>
                  <li>
                    <b> Dyskinesia </b>
                  </li>
                  <li>Xerostomia</li>
                  <li>Taste alterations</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Benztropine (Cogentin®)</strong></td>
              <td>Muscarinic antagonist (antimuscarinic)</td>
              <td>Adjunct for tremor & rigidity in PD</td>
              <td>
                <ul>
                  <li>Blocks CNS muscarinic receptors</li>
                  <li>Reduces cholinergic overactivity</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Antimuscarinic effects</li>
                  <li>
                    <b> Xerostomia (important in dentistry) </b>
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Entacapone</strong></td>
              <td>COMT inhibitor</td>
              <td>Adjunct to levodopa in PD</td>
              <td>
                <ul>
                  <li>Inhibits COMT</li>
                  <li>Reduces peripheral L‑dopa metabolism</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Abnormal taste</li>
                  <li>Orthostatic hypotension</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Selegiline</strong></td>
              <td>MAO‑B inhibitor</td>
              <td>Adjunct in PD to prolong DA action</td>
              <td>
                <ul>
                  <li>Inhibits MAO‑B</li>
                  <li>Decreases dopamine metabolism in CNS</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Xerostomia</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>Chlorpromazine / Fluphenazine / Haloperidol</strong>
              </td>
              <td>First‑generation (typical) antipsychotics</td>
              <td>
                <ul>
                  <li>Psychosis</li>
                  <li>Acute mania</li>
                  <li>Tourette syndrome</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    D2 receptor
                    <b> antagonists </b>
                    (mesolimbic)
                  </li>
                  <li>Reduce psychotic symptoms</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>High risk extrapyramidal symptoms (EPS)</li>
                  <li>
                    <b> Tardive dyskinesia (especially haloperidol) </b>
                  </li>
                  <li>Anticholinergic/autonomic effects</li>
                  <li>Xerostomia</li>
                  <li>Orthostatic hypotension</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Clozapine</strong></td>
              <td>Second‑generation (atypical) antipsychotic</td>
              <td>Refractory schizophrenia</td>
              <td>
                <ul>
                  <li>Blocks 5‑HT2 and D1 receptors</li>
                  <li>Also blocks muscarinic receptors</li>
                  <li>Also blocks histaminic receptors</li>
                  <li>Also blocks α‑adrenergic receptors</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    <b> Agranulocytosis (requires CBC monitoring) </b>
                  </li>
                  <li>Metabolic effects</li>
                  <li>Sedation</li>
                  <li>Xerostomia</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Risperidone</strong></td>
              <td>Second‑generation antipsychotic</td>
              <td>
                <ul>
                  <li>Schizophrenia</li>
                  <li>Bipolar mania</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Blocks 5‑HT2 receptors > D2 receptors</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Metabolic side effects</li>
                  <li>Sedation</li>
                  <li>Autonomic effects including xerostomia</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Donepezil</li>
                  <li>Rivastigmine</li>
                </strong>
              </td>
              <td>Acetylcholinesterase inhibitor</td>
              <td>
                <li>Dementia due to Alzheimer disease</li>
                <li>Parkinson disease–associated dementia (Rivastigmine)</li>
              </td>
              <td>
                <ul>
                  <li>
                    Reversibly inhibits centrally active acetylcholinesterase
                  </li>
                  <li>Increases acetylcholine</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Nausea</li>
                  <li>Diarrhea</li>
                  <li>Sleep disturbances</li>
                  <li>Bradycardia</li>
                  <li>Hypotension</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Memantine</strong></td>
              <td>NMDA receptor antagonist</td>
              <td>Moderate–severe Alzheimer disease (adjunct)</td>
              <td>
                <ul>
                  <li>Blocks NMDA receptors (glutamate receptors)</li>
                  <li>Limits calcium influx</li>
                  <li>Reduces excitotoxicity</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Dizziness</li>
                  <li>Other CNS effects</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Aducanumab (Aduhelm®)</strong></td>
              <td>Amyloid‑directed monoclonal antibody (IV)</td>
              <td>Alzheimer disease (targets amyloid plaques)</td>
              <td>
                <ul>
                  <li>Reduces amyloid β plaques</li>
                  <li>Antibody‑mediated clearance</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>IV therapy risks</li>
                  <li>
                    Disease‑modifying intent (requires specific clinical
                    guidance)
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Riluzole (Exservan®)</strong></td>
              <td>ALS agent (glutamate modulator)</td>
              <td>Amyotrophic lateral sclerosis</td>
              <td>
                <ul>
                  <li>Inhibits glutamate release</li>
                  <li>Inactivates sodium channels</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Nausea</li>
                  <li>
                    <b> Oral hypoesthesia </b>
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>Resperine</strong>
              </td>
              <td>Antihypertensive</td>
              <td>Antihypertensive</td>
              <td>
                <ul>
                  <li>
                    Inhibit packaging of <b>catecholamines</b> and
                    <b>serotonin</b> by binding to VMAT
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Mood Swings</li>
                  <li>Depression</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Amitriptyline / Clomipramine</strong></td>
              <td>Tricyclic antidepressants (TCAs)</td>
              <td>
                <ul>
                  <li>Major depression</li>
                  <li>OCD (clomipramine)</li>
                  <li>Neuropathic pain</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Inhibit reuptake of norepinephrine (NE) via NET</li>
                  <li>Inhibit reuptake of serotonin (5‑HT) via SERT</li>
                  <li>Block α‑adrenergic receptors</li>
                  <li>Block histaminic receptors</li>
                  <li>Block muscarinic receptors</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Antimuscarinic effects (including xerostomia)</li>
                  <li>Orthostatic hypotension (α‑adrenergic)</li>
                  <li>Sedation (histaminic)</li>
                  <li>Tachycardia (sympathomimetic)</li>
                  <li>
                    Interacts with
                    <b> benzodiazepines </b>
                  </li>
                  <li>
                    <b> Potentiates epinephrine in local anesthesia </b>
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Phenelzine</strong></td>
              <td>Monoamine oxidase inhibitor (MAOI)</td>
              <td>Refractory depression</td>
              <td>
                <ul>
                  <li>Inactivates monoamine oxidase enzymes</li>
                  <li>Increases monoamine concentrations</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Drowsiness</li>
                  <li>Orthostatic hypotension</li>
                  <li>Xerostomia</li>
                  <li>Constipation</li>
                  <li>
                    <b>
                      Dangerous tyramine food interactions → hypertensive crisis
                      (tyramine pressor response)
                    </b>
                  </li>
                  <li>
                    <b>
                      Potentiates sympathomimetics (monitor epinephrine use)
                    </b>
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong
                  >Fluoxetine / Sertraline / Citalopram / Escitalopram</strong
                >
              </td>
              <td>Selective serotonin reuptake inhibitors (SSRIs)</td>
              <td>
                <ul>
                  <li>First‑line for major depression</li>
                  <li>PTSD</li>
                  <li>OCD</li>
                  <li>Anxiety disorders</li>
                  <li>Panic disorder</li>
                  <li>Orofacial pain</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Selective inhibition of SERT</li>
                  <li>Increased synaptic serotonin</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>GI irritation</li>
                  <li>Sexual dysfunction</li>
                  <li>Weight changes</li>
                  <li>Increased suicidal thoughts in younger patients</li>
                  <li>
                    <b> Bruxism </b>
                  </li>
                  <li>Risk of serotonin syndrome</li>
                  <li>
                    <b>
                      Drug interactions with NSAIDs (increased GI bleed risk)
                    </b>
                  </li>
                  <li>
                    Fluoxetine and <b> paroxetine </b> inhibit
                    <b> CYP2D6 </b>
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Venlafaxine / Duloxetine</strong></td>
              <td>Serotonin‑norepinephrine reuptake inhibitors (SNRIs)</td>
              <td>
                <ul>
                  <li>Depression</li>
                  <li>Duloxetine also used for neuropathic pain</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Inhibit reuptake of serotonin</li>
                  <li>Inhibit reuptake of norepinephrine</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Similar to SSRIs (GI effects)</li>
                  <li>
                    <b> Sexual dysfunction </b>
                  </li>
                  <li>
                    <b> Bruxism </b>
                  </li>
                  <li>Increased blood pressure</li>
                  <li>Increased heart rate</li>
                  <li>Insomnia</li>
                  <li>Anxiety</li>
                  <li>Xerostomia</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Ketamine / Esketamine</strong></td>
              <td>Rapid‑acting antidepressant (NMDA antagonist)</td>
              <td>Treatment‑resistant depression</td>
              <td>
                <ul>
                  <li>Enhances glutamate release</li>
                  <li>Blocks NMDA receptors</li>
                  <li>Increases BDNF</li>
                  <li>Enhances neuroplasticity</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Increased blood pressure</li>
                  <li>
                    <b> Potential tolerance and dependence </b>
                  </li>
                  <li>Dizziness</li>
                  <li>
                    <b> Sialorrhea </b>
                  </li>
                  <li>Altered taste</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Trazodone (‑zodone)</strong></td>
              <td>Serotonin receptor antagonist (5‑HT2a antagonist)</td>
              <td>
                <ul>
                  <li>Depression</li>
                  <li>Often used for sedative properties</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Blocks selective serotonin receptors (5‑HT2a)</li>
                  <li>Minor effects on other receptors</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Sedation</li>
                  <li>Xerostomia</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Bupropion</strong></td>
              <td>Dopamine‑norepinephrine reuptake inhibitor</td>
              <td>
                <ul>
                  <li>Depression</li>
                  <li>Tobacco cessation</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Increases synaptic dopamine by inhibiting reuptake</li>
                  <li>
                    Increases synaptic norepinephrine by inhibiting reuptake
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Lower risk of sexual dysfunction</li>
                  <li>
                    <b> Seizure risk at high doses </b>
                  </li>
                  <li>Xerostomia (possible)</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>St. John's Wort (hyperforin)</strong></td>
              <td>Herbal antidepressant (OTC)</td>
              <td>
                <ul>
                  <li>Mild–moderate depression</li>
                  <li>Mood swings</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Active ingredient hyperforin</li>
                  <li>Multiple actions</li>
                  <li>Enzyme induction</li>
                </ul>
              </td>
              <td>
                <ul>
                  <b>
                    <li>Induces CYP3A4</li>
                    <li>Induces CYP2C9</li>
                    <li>Many drug interactions</li>
                    <li>May potentiate MAOIs</li>
                    <li>May potentiate SSRIs</li>
                    <li>Increased risk of serotonin syndrome</li>
                  </b>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Lithium carbonate</strong></td>
              <td>Mood stabilizer</td>
              <td>
                <ul>
                  <li>Bipolar disorder (mania)</li>
                  <li>Bipolar depression maintenance</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Exact mechanism unknown</li>
                  <li>Modulates neurotransmitter release</li>
                  <li>Modulates intracellular signaling</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    <b> Narrow therapeutic index </b>
                  </li>
                  <li>Xerostomia</li>
                  <li>
                    <b> Metallic taste </b>
                  </li>
                  <li>Sedation</li>
                  <li>
                    <b>
                      Polyuria and polydipsia (nephrogenic diabetes insipidus)
                    </b>
                  </li>
                  <li>Tremor</li>
                  <li><b> NSAIDs increase lithium levels </b></li>
                  <li>
                    <b> Some antibiotics increase lithium levels </b>
                  </li>
                  <li>Renal excretion</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Valproic acid</strong></td>
              <td>Anticonvulsant (used in bipolar)</td>
              <td>
                <ul>
                  <li>Bipolar disorder</li>
                  <li>Seizures</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Multiple anticonvulsant mechanisms</li>
                  <li>Potentiates GABA</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Teratogen (spina bifida)</li>
                  <li>Thrombocytopenia (bleeding risk)</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Carbamazepine</strong></td>
              <td>Anticonvulsant (used in bipolar)</td>
              <td>
                <ul>
                  <li>Bipolar disorder</li>
                  <li>Seizures</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Blocks voltage‑gated sodium channels</li>
                  <li>Provides mood stabilization effects</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Teratogen (cleft palate)</li>
                  <li>Bone marrow suppression</li>
                </ul>
              </td>
            </tr>
          </tbody>
        </table>
      </details>
      <br />
      <!-- Lecture 5 -->
      <details>
        <summary>Lecture 5: Drugs Acting on the Cardiovascular System</summary>
        <div class="blur-section">
          <b>CYPs: </b>
          <span class="blur-target">
            Statins (Atorvastatin, Simvastatin), Quinidine, Amiodarone,
            Diltizaem, Digoxin
          </span>
        </div>
        <div class="blur-section">
          <b>Macrolides: </b>
          <span class="blur-target">
            Quinidine, Amiodarone, Diltizaem, Digoxin
          </span>
        </div>
        <div class="blur-section">
          <b>Azoles antifungal: </b>
          <span class="blur-target">
            Statins (Atorvastatin, Simvastatin), Quinidine
          </span>
        </div>
        <table>
          <thead>
            <tr>
              <th>Drug</th>
              <th>Class</th>
              <th>Main indication(s)</th>
              <th>Mechanism (brief)</th>
              <th>Major adverse effects / dental implications</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>Nitroglycerin</strong></td>
              <td><strong>Organic nitrate (Vasodilator)</strong></td>
              <td>Acute angina (sublingual and stable)</td>
              <td>
                <li>
                  Converted to NO → ↑cGMP → ↑Desphosphorylation of myosin light
                  chains → vascular smooth muscle relaxation (↓preload, modest
                  ↓afterload, coronary vasodilation)
                </li>
                <li>Vasodilation increases blood supply to the heart muscle</li>
              </td>
              <td>
                <li>
                  <b> Headache </b>
                </li>
                <li>Orthostatic hypotension</li>
                <li>
                  <b> Facial flushing </b>
                </li>
                <li>Xerostomia</li>
                <li>Keep for emergencies</li>
              </td>
            </tr>
            <tr>
              <td><strong>Isosorbide dinitrate</strong></td>
              <td><strong>Organic nitrate</strong></td>
              <td>Angina (longer-acting)</td>
              <td>Converted to NO → vasodilation</td>
              <td>
                <li>Orthostatic hypotension</li>
                <li>Headache</li>
              </td>
            </tr>
            <tr>
              <td><strong>Aspirin</strong></td>
              <td><strong>Antiplatelet (NSAID)</strong></td>
              <td>
                <li>
                  Prevention of arterial thrombosis in CAD (coronary artery
                  disease)
                </li>
                <li>ACS (Acute coronary syndrome)</li>
              </td>
              <td>Irreversibly inhibits COX → ↓TxA2 → ↓platelet aggregation</td>
              <td>Bleeding risk relevant to dental procedures.</td>
            </tr>
            <tr>
              <td><strong>Atorvastatin / Simvastatin</strong></td>
              <td><strong>HMG‑CoA reductase inhibitors (Statins)</strong></td>
              <td>
                <li>
                  Hyperlipidemia (Hypercholesterolemia and Hypertriglyceridemia)
                </li>
                <li>Reduce LDL/TG</li>
              </td>
              <td>
                <li>
                  Inhibit HMG‑CoA reductase → ↓cholesterol synthesis → ↑LDL
                  catabolism → ↓TG Levels
                </li>
                <li>Competitive inhibitors in liver</li>
              </td>
              <td>
                <b>
                  <li>Myalgia → myopathy → (rare) rhabdomyolysis</li>
                  <li>Hepatotoxicity</li>
                  <li>↑ Liver enzymes</li>
                  <li>Interactions with azoles/erythromycin</li>
                  <li>Contraindicated in pregnancy</li>
                </b>
                <li>
                  Statins can increase the anticoagulant effect of
                  <b> warfarin </b>
                </li>
              </td>
            </tr>
            <tr>
              <td><strong>Ezetimibe</strong></td>
              <td><strong>Cholesterol absorption inhibitor</strong></td>
              <td>Adjunct/alternative to statins</td>
              <td>
                Inhibits intestinal cholesterol absorption → ↓hepatic
                cholesterol
              </td>
              <td>Generally well tolerated.</td>
            </tr>
            <tr>
              <td><strong>Quinidine</strong></td>
              <td>
                <strong>Class I antiarrhythmic (Na⁺ channel blocker)</strong>
              </td>
              <td>Atrial &amp; ventricular tachyarrhythmias</td>
              <td>
                Blocks Na⁺ channels → ↓conduction velocity &amp; excitability
              </td>
              <td>
                <li>Anticholinergic (xerostomia)</li>
                <b>
                  <li>Thrombocytopenia (gingival bleeding)</li>
                  <li>CYP3A4 interactions (macrolides/azoles).</li>
                  <li>
                    Inihibtor for CYP2D6 and may effect metabolism of opioid
                    analgesics
                  </li>
                  <li>Thrombocytopenia risk</li>
                  <li>
                    Cinchonism: Blurred vision, tinnitus, disorientation,
                    psychosis
                  </li>
                </b>
              </td>
            </tr>
            <tr>
              <td><strong>Disopyramide</strong></td>
              <td><strong>Class I antiarrhythmic</strong></td>
              <td>Tachyarrhythmias</td>
              <td>Na⁺ channel blockade → slows conduction</td>
              <td>
                <li>ESPECIALLY: Anticholinergic effects (xerostomia)</li>
                <b>
                  <li>Thrombocytopenia risk</li>
                </b>
              </td>
            </tr>
            <tr>
              <td><strong>Lidocaine</strong></td>
              <td>
                <strong>Class I antiarrhythmic / local anesthetic</strong>
              </td>
              <td>
                <li>Ventricular arrhythmias (acute)</li>
                <li>Local anesthesia</li>
              </td>
              <td>Na⁺ channel blockade (preferential in ischemic tissue)</td>
              <td>Fewer anticholinergic effects vs other Class I agents.</td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Metoprolol (Selective)</li>
                  <li>Atenolol (Selective)</li>
                  <li>Propranolol (Non-selective)</li>
                </strong>
              </td>
              <td><strong>Class II (β‑blocker)</strong></td>
              <td>
                <li>Rate control in tachyarrhythmias</li>
                <li>Arrhythmias</li>
                <li>HTN</li>
                <li>Angina</li>
                <li>Heart Failure</li>
                <li><b>No drug to drug interaction listed</b></li>
              </td>
              <td>
                <li>Target pacemaker cells and kidney</li>
                <li>
                  β1 blockade → ↓HR, Prolong AV conduction, ↓contractility
                </li>
                <li>
                  Block β1 receptors (response to Epi and NE) → ↓HR &amp; ↓
                  firing at SA, AV Nodes &amp; CO
                </li>
                <li>
                  Block β1 receptors in kidney → ↓renin production →
                  ↓angiotensin II
                </li>
                <li>Block β2 receptors (Propranolol)</li>
              </td>
              <td>
                <li>Bradycardia</li>
                <li>Orthostatic hypotension</li>
                <b>
                  <li>Monitor epinephrine use in dental local anesthesia</li>
                </b>
              </td>
            </tr>
            <tr>
              <td><strong>Amiodarone</strong></td>
              <td>
                <strong>Class III antiarrhythmic (K⁺ channel blocker)</strong>
              </td>
              <td>
                <li>Broad‑spectrum antiarrhythmic (ventricular arrhythmias)</li>
                <li>Effective in severe ventricular tachyarrhythmias</li>
              </td>
              <td>
                Blocks K⁺ outflux during repolarization → prolonged refractory
                period in cardiomyocytes
              </td>
              <td>
                <b>
                  <li>Pulmonary fibrosis</li>
                  <li>Neuropathy</li>
                  <li>Hepatotoxicity</li>
                </b>
                <li>Altered taste</li>
                <b>
                  <li>Many CYP interactions (affects codeine, fentanyl).</li>
                  <li>May induce arrhythmias</li>
                </b>
              </td>
            </tr>
            <tr>
              <td><strong>Diltiazem / Verapamil</strong></td>
              <td><strong>Class IV (non‑dihydropyridine CCBs)</strong></td>
              <td>
                <li>Rate control in arrhythmias</li>
                <li>Angina</li>
                <li>HTN</li>
              </td>
              <td>
                <li>Prevent repolarization stage in pacemaker cells</li>
                <li>
                  Block L‑type Ca²⁺ channels in myocardium → slow SA/AV
                  conduction, ↓contractility
                </li>
                <li>Prolong effective refractory period</li>
              </td>
              <td>
                <li>Bradycardia</li>
                <li>Hypotension</li>
                <b>
                  <li>Gingival hyperplasia</li>
                  <li>Interacts with macrolides via CYP3A4. (diltiazem)</li>
                </b>
              </td>
            </tr>
            <tr>
              <td><strong>Nifedipine / Amlodipine</strong></td>
              <td><strong>Dihydropyridine CCBs</strong></td>
              <td>
                <li>HTN</li>
                <li>Angina</li>
              </td>
              <td>
                Block vascular Ca²⁺ channels → arteriolar vasodilation
                (↓afterload)
              </td>
              <td>
                <li>Dizziness</li>
                <li>Orthostatic hypotension</li>
                <b>
                  <li>
                    Nifedipine &amp; amlodipine may cause gingival hyperplasia.
                  </li>
                </b>
              </td>
            </tr>
            <tr>
              <td><strong>Isradipine</strong></td>
              <td><strong>Dihydropyridine CCB (exception)</strong></td>
              <td>HTN</td>
              <td>Arteriolar Ca²⁺ channel blockade → vasodilation</td>
              <td>
                <b>
                  Typically does not cause gingival hyperplasia (exception).
                </b>
              </td>
            </tr>
            <tr>
              <td><strong>Atropine</strong></td>
              <td><strong>Antimuscarinic</strong></td>
              <td>Management of bradyarrhythmias</td>
              <td>
                <li>
                  Blocks muscarinic ACh receptors → ↑sinus rate &amp; ↑AV
                  conduction &amp; ↑SA conduction velocity
                </li>
                <li>↓refractory period</li>
              </td>
              <td>
                <li>Dry mouth (xerostomia)</li>
                <b>
                  <li>Mydriasis</li>
                </b>
              </td>
            </tr>
            <tr>
              <td><strong>Digoxin (Digox / Lanoxin)</strong></td>
              <td><strong>Cardiac glycoside (positive inotrope)</strong></td>
              <td>
                <li>Heart failure (HFrEF)</li>
                <li>Rate control in AF</li>
              </td>
              <td>
                Inhibits Na⁺/K⁺ ATPase → ↑intracellular Na⁺ → ↓Na⁺/Ca²⁺ exchange
                → ↑intracellular Ca²⁺ → ↑contractility
              </td>
              <td>
                <b>
                  <li>Narrow therapeutic index</li>
                  <li>
                    Toxicity → nausea, vomiting, confusion, blurred vision
                  </li>
                  <li>Macrolides &amp; tetracyclines can ↑digoxin levels</li>
                  <li>Arrhythmia risk with vasoconstrictors.</li>
                  <li>Hyperkalemia</li>
                  <li>
                    CYP450 inducers may lower concentration of active drug
                  </li>
                </b>
              </td>
            </tr>
            <tr>
              <td><strong>Dobutamine</strong></td>
              <td>
                <li>
                  <strong>β‑agonist (β1 &gt; β2)</strong>
                </li>
                <li>
                  <strong>Positive inotrope</strong>
                </li>
              </td>
              <td>Acute decompensated HF (IV)</td>
              <td>β1 agonism → ↑inotropy (some vasodilation via β2)</td>
              <td>
                <li>Used IV in acute settings</li>
                <li>Monitor hemodynamics</li>
              </td>
            </tr>
            <tr>
              <td><strong>Milrinone</strong></td>
              <td>
                <li>
                  <strong>PDE‑3 inhibitor</strong>
                </li>
                <li>
                  <strong>Positive inotrope</strong>
                </li>
              </td>
              <td>Acute HF / inotropic support (IV)</td>
              <td>
                <li>PDE3 inhibition → ↑cAMP → ↑Ca²⁺ influx</li>
                <li>
                  Elevated intracellular Ca²⁺ levels and enhanced excitation
                  concentration
                </li>
              </td>
              <td>
                <li>Arrhythmias, hypotension</li>
                <li>Used as IV infusion in acute settings</li>
              </td>
            </tr>
            <tr>
              <td><strong>Dapagliflozin (Farxiga)</strong></td>
              <td><strong>SGLT2 inhibitor</strong></td>
              <td>
                <li>Heart failure (↓hospitalization/mortality)</li>
                <li>With or without Diabetes</li>
              </td>
              <td>
                Inhibits renal SGLT2 → ↑glucosuria → osmotic diuresis (↓preload)
              </td>
              <td>
                <li>Orthostatic hypotension</li>
                <li>
                  <b>
                    Dental: hypoglycemia risk in diabetic patients under stress.
                  </b>
                </li>
              </td>
            </tr>
            <tr>
              <td><strong>Prazosin (Minipress)</strong></td>
              <td><strong>α1‑blocker</strong></td>
              <td>Refractory HTN (2nd‑line)</td>
              <td>
                Arterial &amp; venous smooth muscle relaxation → ↓peripheral
                resistance
              </td>
              <td>
                <li>
                  <b> Reflex tachycardia </b>
                </li>
                <li>Orthostatic hypotension</li>
              </td>
            </tr>
            <tr>
              <td><strong>Clonidine (Catapres)</strong></td>
              <td><strong>α2‑agonist (central)</strong></td>
              <td>
                <li>HTN (not first‑line)</li>
                <li>ADHD</li>
              </td>
              <td>
                Central α2 agonism → ↓sympathetic outflow (NE and Ach)→
                ↓peripheral resistance
              </td>
              <td>
                <li>Xerostomia</li>
                <li>Orthostatic hypotension</li>
                <li>Sedation</li>
                <li>Confusion (dental relevance: dry mouth)</li>
              </td>
            </tr>
            <tr>
              <td>
                <b> Methyldopa </b>
              </td>
              <td>
                <b> α2‑agonist </b>
              </td>
              <td>
                <li>HT (First line)</li>
                <li>Pregnancy</li>
              </td>
              <td>
                Converted to methylnorepinephrine which diminishes adrenergic
                outflow from the CNS
              </td>
              <td>
                <li>Sedation</li>
                <li>Drowsiness</li>
              </td>
            </tr>
          </tbody>
        </table>
      </details>
      <!-- Lecture 6 -->
      <br />
      <details>
        <summary>Lecture 6 - Renal pharmacology</summary>
        <table>
          <thead>
            <tr>
              <th>Drug class</th>
              <th>Example(s)</th>
              <th>Mechanism of action (MOA)</th>
              <th>Indications</th>
              <th>Key adverse effects / precautions</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>ACE inhibitors</strong></td>
              <td>
                <li>
                  <strong>Captopril</strong>
                </li>
                <li>
                  <strong>Enalapril</strong>
                </li>
              </td>
              <td>
                <li>
                  Block angiotensin‑converting enzyme → ↓ Ang II formation → ↓
                  preload (blood volume) and ↓ afterload (peripheral
                  resistance).
                  <strong>Also ↑ bradykinin</strong> (enhances vasodilation).
                </li>
                <li>
                  Decreased aldosterone → ↑Na⁺ and water excretion, ↑K⁺
                  retention.
                </li>
              </td>
              <td>
                <li>
                  First‑line for hypertension in patients with heart disease,
                  diabetes, or chronic kidney disease.
                </li>
              </td>
              <td>
                <ul>
                  <b>
                    <li>Dry cough</li>
                    <li>Angioedema</li>
                  </b>
                  <li>Hyperkalemia (↓ aldosterone)</li>
                  <li>Orthostatic hypotension</li>
                  <li>Altered Taste</li>
                  <li><strong>contraindicated in pregnancy</strong>.</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Renin inhibitor</strong></td>
              <td>
                <strong>Aliskiren (Tekturna®)</strong>
              </td>
              <td>
                Selective renin inhibitor → blocks conversion of angiotensinogen
                to Ang I.
              </td>
              <td>Hypertension.</td>
              <td>
                <ul>
                  <li>May cause angioedema (less than ACEi)</li>
                  <li>
                    <strong>contraindicated in pregnancy</strong>
                  </li>
                  <li>Do not combine with ACEi/ARB</li>
                  <b>
                    <li>Metabolized by CYP3A4.</li>
                  </b>
                  <li>
                    Prescribing NSAIDS for more than 5 days may diminish
                    effectiveness
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Angiotensin II receptor blockers (ARBs)</strong></td>
              <td>
                <li>
                  <strong>Losartan</strong>
                </li>
                <li>
                  <strong>Valsartan</strong>
                </li>
              </td>
              <td>
                Competitive antagonists at AT1 receptor → block Ang II effects
                (vasodilation, block aldosterone). Do
                <strong>not</strong> increase bradykinin.
              </td>
              <td>
                First‑line option for hypertension (esp. diabetes, HF, CKD).
              </td>
              <td>
                <ul>
                  <li>More likely to cause Hypotension over ACEi</li>
                  <li>Hyperkalemia</li>
                  <li>Less cough/angioedema than ACEi</li>
                  <li><strong>contraindicated in pregnancy</strong>.</li>
                  <li>Avoid combining with ACEi.</li>
                  <li>
                    Prescribing NSAIDS for more than 5 days may diminish
                    effectiveness
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Other CVS agents (brief)</strong></td>
              <td>
                <li>
                  <strong>Colchicine (0.5 mg/day)</strong>
                </li>
                <li>
                  <strong>Aspirin (81 mg/day)</strong>
                </li>
              </td>
              <td>
                <li>
                  <strong> Colchicine: </strong>
                  anti‑inflammatory (used low dose for CV risk
                  reduction)(Anti-gout)
                </li>
                <li>
                  <strong> Aspirin: </strong>
                  antiplatelet (cardioprotection)
                </li>
              </td>
              <td>
                <li>
                  <strong> Colchicine: </strong>
                  reduce MI/stroke risk in certain atherosclerotic patients.
                </li>
                <li>
                  <strong> Aspirin: </strong>
                  cardioprotection.
                </li>
              </td>
              <td>
                <ul>
                  <li>
                    <strong> Aspirin: </strong>
                    affects hemostasis (dose/interaction dependent).
                  </li>
                  <li>
                    <strong> Colchicine: </strong>
                    GI and drug interactions (details not expanded here).
                  </li>
                </ul>
              </td>
            </tr>

            <tr>
              <td><strong>Osmotic diuretics</strong></td>
              <td>
                <strong>Mannitol (Osmitrol®)</strong>
              </td>
              <td>
                Filtered but not reabsorbed → increases tubular osmolarity →
                retains water in tubule → facilitates water excretion and
                prevents its reabsorption
              </td>
              <td>
                <li>IV for cerebral edema</li>
                <li>Elevated intracranial pressure</li>
              </td>
              <td>
                <ul>
                  -
                </ul>
              </td>
            </tr>

            <tr>
              <td><strong>Carbonic anhydrase inhibitors</strong></td>
              <td>
                <strong>Acetazolamide (Diamox®)</strong>
              </td>
              <td>
                Inhibit carbonic anhydrase → reduce HCO3− formation and decrease
                Na+/H+ exchange → mild bicarbonate diuresis.
              </td>
              <td>
                <li>Reduce intraocular pressure in glaucoma</li>
                <li>
                  Prophylaxis for altitude sickness. (Overall weak diuretic.)
                </li>
              </td>
              <td>
                <ul>
                  -
                </ul>
              </td>
            </tr>

            <tr>
              <td><strong>Loop diuretics</strong></td>
              <td>
                <li>
                  <strong>Furosemide (short duration (acute))</strong>
                </li>
                <li>
                  <strong>Bumetanide (long)</strong>
                </li>
                <li>
                  <strong>Torsemide (long)</strong>
                </li>
              </td>
              <td>
                <li>
                  Block Na⁺–K⁺–2Cl⁻ symporter in thick ascending limb → potent
                  natriuresis and diuresis
                </li>
                <li>↑ excretion of Na⁺, K⁺, Ca²⁺, Mg²⁺.</li>
              </td>
              <td>
                <li>Acute pulmonary edema</li>
                <li>Edema from renal/liver disease</li>
                <li>Chronic CHF</li>
                <li>HTN adjunct</li>
                <li>Acute hypercalcemia (with renal failure).</li>
              </td>
              <td>
                <ul>
                  <li>Hypokalemia</li>
                  <li>Dose‑related ototoxicity</li>
                  <li>Nephrotoxicity</li>
                  <li>Orthostatic hypotension</li>
                  <li>Hyperuricemia</li>
                  <li>Hypomagnesemia</li>
                  <li>
                    Sigmoidal dose‑response (threshold &amp; ceiling effects)
                  </li>
                  <li>
                    Drug interaction: NSAIDs can blunt effect and increase
                    nephrotoxicity.
                  </li>
                  <li>Exacerbate Gout attacks</li>
                </ul>
              </td>
            </tr>

            <tr>
              <td><strong>Thiazide diuretics</strong></td>
              <td>
                <li>
                  <strong>Chlorothiazide</strong>
                </li>
                <li>
                  <strong>Hydrochlorothiazide (HCTZ)</strong>
                </li>
              </td>
              <td>
                <li>
                  Inhibit Na+/Cl− reabsorption in distal convoluted tubule → ↑
                  NaCl excretion and <strong>↑ Ca2+ reabsorption</strong>
                </li>
                <li>
                  Reduce peripheral vascular resistance long‑term (mechanism not
                  fully clear).
                </li>
              </td>
              <td>
                <li>Hypertension</li>
                <li>Edema (heart/liver/kidney)</li>
                <li>Prevention of calcium kidney stone</li>
                <li>Nephrogenic diabetes Insipidus</li>
              </td>
              <td>
                <ul>
                  <li>Hypokalemia</li>
                  <li>Hyperuricemia</li>
                  <li><strong>Hypercalcemia</strong>,</li>
                  <li>Hyponatremia</li>
                  <li>Hyperglycemia</li>
                  <li>Cross‑allergy with sulfonamide antibiotics</li>
                </ul>
              </td>
            </tr>

            <tr>
              <td><strong>Potassium‑sparing diuretics</strong></td>
              <td>
                <li>
                  <strong> Spironolactone (aldosterone antagonist) </strong>
                </li>
                <li>
                  <strong>Amiloride</strong>
                </li>
              </td>
              <td>
                <li>
                  <b> Spironolactone: </b>
                  aldosterone receptor antagonist → ↓ Na+ reabsorption, ↓ K+
                  secretion, ↓ H+ secretion in collecting duct
                </li>
                <li>
                  <b> Amiloride: </b>
                  blocks epithelial Na+ channels (ENaC) in collecting duct, → ↓
                  Na+ reabsorption, ↓ K+ secretion → ↑ Na+ excretion while
                  preserving potassium; Can be used with other diuretics
                </li>
              </td>
              <td>
                <li>Edema</li>
                <li>Hypokalemia prevention</li>
                <li>Refractory HTN (often combined with thiazide/loop)</li>
              </td>
              <td>
                <ul>
                  <li>
                    Hyperkalemia (↑ arrhythmia risk). Spironolactone may cause
                    gynecomastia (androgen receptor effects).
                  </li>
                </ul>
              </td>
            </tr>
          </tbody>
        </table>
      </details>
      <br />
      <details>
        <summary>Lecture 7 - Drugs Affecting the Respiratory System</summary>
        <table>
          <thead>
            <tr>
              <th>Drug</th>
              <th>Class</th>
              <th>Indications</th>
              <th>Mechanism of Action</th>
              <th>Major adverse effects</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>
                <strong>
                  <li>Albuterol</li>
                  <li>Levalbuterol</li>
                </strong>
              </td>
              <td>Short-acting β2-agonist (SABA)</td>
              <td>Acute relief of asthma symptoms (reliever)</td>
              <td>
                Activates β2-adrenergic receptors → increases cAMP →
                bronchodilation (decreased Ca2+ availability)
              </td>
              <td>
                <ul>
                  <li>Skeletal muscle tremor</li>
                  <li>Increased heart rate</li>
                  <li>With chronic use receptor down-regulation</li>
                  <li>Dry mouth/unpleasant taste</li>
                  <li>Candidiasis rare</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Salmeterol</li>
                  <li>Formoterol (Longer duration and & onset)</li>
                </strong>
              </td>
              <td>Long-acting β2-agonist (LABA)</td>
              <td>
                <li>
                  Combined with inhaled corticosteroids for moderate–severe
                  asthma
                </li>
                <li>Monotherapy in COPD</li>
              </td>
              <td>
                Activates β2-adrenergic receptors → increases cAMP → prolonged
                bronchodilation
              </td>
              <td>
                <ul>
                  <li>Skeletal muscle tremor</li>
                  <li>Increased heart rate</li>
                  <li>With chronic use receptor down-regulation</li>
                  <li>Dry mouth/unpleasant taste</li>
                  <li>Candidiasis rare</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Ipratropium</li>
                  <li>Tiotropium (LABA)</li>
                </strong>
              </td>
              <td>Short-acting muscarinic antagonist (SAMA)</td>
              <td>
                <li>
                  Add-on treatment for asthma; maintenance therapy for COPD
                </li>
                <li>Rhinitis</li>
              </td>
              <td>
                Competitive antagonist at M3 muscarinic receptors → blocks
                Ach-mediated bronchoconstriction and reduces mucus secretion
              </td>
              <td>
                <ul>
                  <li>Low systemic absorption</li>
                  <li>Dry mouth</li>
                  <li>Altered taste</li>
                  <li>Urinary retention (especially in elderly)</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Theophylline (Euxophyllin, THEO‑24)</strong></td>
              <td>Methylxanthine (nonselective PDE inhibitor)</td>
              <td>
                Asthma and COPD — especially severe/refractory cases (not
                first-line)
              </td>
              <td>
                <li>
                  Weak, nonspecific phosphodiesterase (PDE) inhibition → ↑cAMP;
                  bronchodilator effects and decreased intracellular Ca2+
                </li>
                <li>
                  Administered only through oral route because systemically it
                  is ineffective by inhaled route
                </li>
                <li>Poorly understood</li>
              </td>
              <td>
                <ul>
                  <li>Headache</li>
                  <li>Vomiting</li>
                  <li>Restlessness/insomnia</li>
                  <li>High levels → cardiac arrhythmias</li>
                  <li>Seizures</li>
                  <li>
                    Significant drug interactions (CYP‑450 inhibitors like
                    erythromycin, azoles)
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Beclomethasone</li>
                  <li>Fluticasone (Intranasal)</li>
                  <li>Budesonide</li>
                </strong>
              </td>
              <td>
                <li>Steroids (Can be used with LABAs)</li>
                <li>Used as inhaler or oral tablets</li>
                <li>Liver metabolized</li>
              </td>
              <td>
                <li>
                  Long-term control of persistent asthma (first-line as
                  controller)
                </li>
                <li>Short systemic courses for exacerbations</li>
                <li>Inhaled glucocorticoids are less effective in COPD</li>
              </td>
              <td>
                <li>
                  Inhibits phospholipase A2 → reduces arachidonic acid
                  metabolites (leukotrienes/prostaglandins)
                </li>
                <li>Decreases inflammatory cells and mucus production</li>
              </td>
              <td>
                <ul>
                  <li>Hoarseness</li>
                  <li>Throat irritation</li>
                  <li>Cough</li>
                  <li>Oral candidiasis (3–5%)</li>
                  <li>Herpes simplex</li>
                  <li>Nose bleed (fluticasone)</li>
                  <li>Dry mouth</li>
                  <li>
                    Systemic effects possible with oral steroids
                    (growth/osteoporosis, weight gain, diabetes)
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Omalizumab</strong></td>
              <td>Biologic — anti‑IgE monoclonal antibody</td>
              <td>
                <li>
                  Moderate to severe allergic asthma not controlled by
                  corticosteroids
                </li>
                <li>Administered via subcutaneous injection every 2-4 weeks</li>
                <li>Not effective for non-atopic asthma or COPD</li>
              </td>
              <td>
                Binds circulating IgE → prevents IgE binding to mast cells and
                reduces downstream allergic mediator release (↓eosinophils,
                mediators)
              </td>
              <td>
                <ul>
                  <li>Hypersensitivity reactions</li>
                  <li>Injection-site reactions</li>
                  <li>Fever</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Benralizumab</strong></td>
              <td>Biologic — anti‑IL‑5 (monoclonal antibody)</td>
              <td>
                Biologic therapy for eosinophilic/severe asthma (reduces
                eosinophil‑driven inflammation)
              </td>
              <td>
                <li>
                  IL-5 is a main cytokine involved in recruitment, activation,
                  and survival of eosinophils
                </li>
                <li>
                  Blocks IL‑5 action → reduces recruitment, activation and
                  survival of eosinophils → lowers eosinophilic inflammation
                </li>
              </td>
              <td>
                <ul>
                  <li>Hypersensitivity reaction</li>
                  <li>Injection-site reaction</li>
                  <li>Fever</li>
                  <li>Increased infection risk</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Cromolyn</strong></td>
              <td>Mast cell stabilizer (prophylactic anti‑inflammatory)</td>
              <td>
                Prophylaxis to prevent allergic/inflammatory responses in asthma
                (largely outdated)
              </td>
              <td>
                Stabilizes mast cells → prevents degranulation and histamine
                release
              </td>
              <td>
                <ul>
                  <li>Cough</li>
                  <li>Throat irritation</li>
                  <li>Unpleasant taste</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Zileuton</strong></td>
              <td>5‑lipoxygenase (LOX) inhibitor (lipoxygenase inhibitor)</td>
              <td>
                Leukotriene‑mediated asthma (as a lipoxygenase pathway
                inhibitor)
              </td>
              <td>
                Selective inhibition of 5‑lipoxygenase → blocks conversion of
                arachidonic acid to leukotrienes
              </td>
              <td>
                <ul>
                  <li>Hepatotoxicity — contraindicated in liver disease</li>
                  <li>Requires liver enzyme monitoring</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Montelukast</li>
                  <li>Zafrilukast</li>
                </strong>
              </td>
              <td>Leukotriene receptor antagonist (CysLT1 receptor blocker)</td>
              <td>
                Exercise‑induced asthma and allergic asthma; once-daily oral
                therapy
              </td>
              <td>
                Blocks leukotriene receptors → prevents leukotriene-mediated
                bronchoconstriction, eosinophil migration, and airway edema
              </td>
              <td>
                <ul>
                  <strong> Montelukast</strong>
                  <li>Dental pain (~2%)</li>
                  <li>Increased bleeding (thrombocytopenia possible)</li>
                  <li>
                    Potential neuropsychiatric events (boxed warnings especially
                    in pediatric patients)
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Roflumilast</strong></td>
              <td>Phosphodiesterase‑4 (PDE4) inhibitor</td>
              <td>Prevents symptom exacerbations in severe COPD</td>
              <td>
                <li>Inhibits PDE4 in lung → ↑cAMP</li>
                <li>
                  Reduces cytokine release and leukocyte infiltration (not a
                  bronchodilator)
                </li>
              </td>
              <td>
                <ul>
                  <li>Weight loss</li>
                  <li>Nausea</li>
                  <li>Diarrhea</li>
                  <li>Headache</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Cetirizine</li>
                  <li>Loratadine</li>
                </strong>
              </td>
              <td>Second‑generation antihistamine (H1 antagonist)</td>
              <td>Allergic rhinitis / allergy symptoms</td>
              <td>
                Competes with histamine for H1 receptor binding → reduces
                histamine effects
              </td>
              <td>
                <ul>
                  <li>Decreased salivary flow</li>
                  <li>Dry mouth</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Pseudoephedrine</li>
                  <li>Oxymetazoline</li>
                </strong>
              </td>
              <td>Oral α‑adrenergic agonist (systemic decongestant)</td>
              <td>Nasal congestion (oral decongestant)</td>
              <td>
                Stimulates α‑adrenergic receptors in nasal arterioles →
                vasoconstriction → decreased nasal congestion
              </td>
              <td>
                <ul>
                  <li>
                    <strong>Oxymetazoline: </strong>Rebound congestion
                    (Worsening of nasal congestion due to prolonged use of
                    decongestants, sometimes termed nasal spray addiction). Not
                    advised to use ɑ-agaonists for more than 3 consecutive days
                    because it increases the risk of rebound congestion
                  </li>
                  <li><strong>Pseudoephedrine: </strong>Mild dry mouth</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Fluticasone</li>
                  <li>Triamcinolone</li>
                </strong>
              </td>
              <td>Intranasal corticosteroid</td>
              <td>
                Treatment of allergic rhinitis — reduces sneezing, itching,
                rhinorrhea, congestion
              </td>
              <td>
                Local corticosteroid anti‑inflammatory actions (similar PLA2
                inhibition)
              </td>
              <td>
                <ul>
                  <li>Nasal irritation</li>
                  <li>Nosebleed</li>
                  <li>Sore throat</li>
                  <li>Minimal systemic absorption</li>
                </ul>
              </td>
            </tr>
          </tbody>
        </table>
      </details>
      <br />
      <details>
        <summary>Lecture 8: Hemostasis and Anemia</summary>
        <table>
          <thead>
            <tr>
              <th>Drugs</th>
              <th>Class</th>
              <th>Main Indication</th>
              <th>Mechanism of Action</th>
              <th>Major Adverse effects</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><strong> Erythropoietin (EPO)</strong></td>
              <td>Erythropoiesis‑stimulating agent</td>
              <td>Anemia from CKD or chemotherapy</td>
              <td>
                <ul>
                  <li>
                    Stimulates proliferation of erythroid precursors in bone
                    marrow.
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Hypertension</li>
                  <li>↑ risk of cardiovascular events and thrombosis</li>
                  <li>stomatitis</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Darbepoetin</strong></td>
              <td>Erythropoiesis‑stimulating agent</td>
              <td>Anemia (longer‑acting EPO analog)</td>
              <td>
                <ul>
                  <li>
                    Stimulates erythroid precursor proliferation (longer
                    half‑life vs EPO).
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Hypertension</li>
                  <li>thrombosis risk</li>
                  <li>stomatitis</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Hydroxyurea</strong></td>
              <td>Antimetabolite</td>
              <td>Sickle cell disease (increase HbF, reduce crises)</td>
              <td>
                <ul>
                  <li>Increases fetal hemoglobin (HbF)</li>
                  <li>modulates RBC water content &amp; adhesion</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Bone marrow suppression (neutropenia)</li>
                  <li>thrombocytopenia</li>
                  <li>anemia</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Crizanlizumab</strong></td>
              <td>Anti‑P‑selectin monoclonal antibody</td>
              <td>Reduce vaso‑occlusive crises in sickle cell disease</td>
              <td>
                <ul>
                  <li>Blocks P‑selectin → ↓ vascular occlusion.</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>↓ platelet aggregation</li>
                  <li>increased oropharyngeal pain</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Casgevy / Lyfgenia</strong></td>
              <td>Gene editing / gene therapy</td>
              <td>Sickle cell disease (curative intent)</td>
              <td>
                <ul>
                  <li>
                    Ex vivo HSC genetic modification to produce
                    corrected/beneficial HbA<sup>T87Q</sup>.
                  </li>
                </ul>
              </td>
              <td>-</td>
            </tr>
            <tr>
              <td><strong>Vitamin B12 (cobalamin)</strong></td>
              <td>Vitamin replacement</td>
              <td>Pernicious megaloblastic anemia</td>
              <td>
                <ul>
                  <li>
                    Replaces B12 required for RBC maturation/DNA synthesis.
                  </li>
                </ul>
              </td>
              <td>-</td>
            </tr>
            <tr>
              <td><strong>Folic acid (vitamin B9)</strong></td>
              <td>Vitamin replacement</td>
              <td>Folate‑deficiency megaloblastic anemia</td>
              <td>
                <ul>
                  <li>
                    Replaces folate required for DNA synthesis and RBC
                    production.
                  </li>
                </ul>
              </td>
              <td>-</td>
            </tr>
            <tr>
              <td><strong>Ferrous sulfate / Ferrous gluconate</strong></td>
              <td>Oral iron supplements</td>
              <td>Iron deficiency anemia</td>
              <td>
                <ul>
                  <li>Provide Fe<sup>2+</sup> for hemoglobin synthesis</li>
                  <li>Fe<sup>2+</sup> better absorbed in acidic gut.</li>
                  <li>Iron absorbed in duodenum</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>GI upset (nausea, flatulence, constipation)</li>
                  <li>teeth staining (liquid)</li>
                  <li>metallic taste</li>
                  <li>interactions (↓ with Ca, PPIs; ↑ with vitamin C)</li>
                  <li>
                    Simultaenous administration of iron and tetracycline will
                    hinder the GI absorption of both drugs
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Warfarin</strong></td>
              <td>Oral vitamin K antagonist anticoagulant</td>
              <td>
                Prevention/treatment of venous/pulmonary thromboembolism; stroke
                prevention in AF
              </td>
              <td>
                <ul>
                  <li>
                    Inhibits vitamin K epoxide reductase → ↓ γ‑carboxylation of
                    clotting factors II, VII, IX, X and proteins C & S.
                  </li>
                  <li>
                    Metabolized by CYP450, conjugated with glucuronic acid and
                    excreted in urine
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Bleeding (risk ↑ when INR >3)</li>
                  <li>teratogenicity (contraindicated in pregnancy)</li>
                  <li>
                    Drugs that inhib CYP2C9 and CYP3A4 may inhibit metabolism
                    and ↑ risk of bleeding
                  </li>
                  <li>
                    Enzymbe inducers (barbiturates and others) may enhance
                    metabolism
                  </li>
                  <li>Vitamin K decrease treatment efficiency</li>
                  <li>NSAIDs can increase risk of bleeding</li>
                  <li>Aspirin inhibits platelet function</li>
                  <li>
                    Emergency patients administered fresh frozen plasma or
                    prothrombin complex concentrate
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Heparin (unfractionated)</strong></td>
              <td>
                <li>Parenteral anticoagulant</li>
                <li>IV or subcutaneous</li>
              </td>
              <td>Immediate anticoagulation (ACS, DVT, surgical adjunct)</td>
              <td>
                <ul>
                  <li>
                    Binds antithrombin → inactivates thrombin (IIa) and factor
                    Xa.
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Bleeding</li>
                  <li>
                    Heparin‑associated thrombocytopenia (type I) and immune HIT
                    (type II)
                  </li>
                  <li>Hypersensitivity</li>
                  <li>Can be used on pregnant women</li>
                  <li><strong>Protamine sulfate</strong> reversal drug</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>LMWH (e.g., dalteparin)</strong></td>
              <td>
                <li>Low molecular weight heparin</li>
                <li>IV or subcutaneous</li>
              </td>
              <td>Anticoagulation (DVT, etc.)</td>
              <td>
                <ul>
                  <li>
                    POTentiates antithrombin predominantly inhibiting factor Xa
                  </li>
                  <li>longer half‑life and better bioavailability</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Bleeding</li>
                  <li>HIT less common than UFH</li>
                  <li>hypersensitivity</li>
                  <li>Can be used on pregnant women</li>
                  <li><strong>Protamine sulfate</strong> reversal drug</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Desirudin</li>
                  <li>Bivalirudin</li>
                  <li>Dabigatran</li>
                </strong>
              </td>
              <td>
                <li>Direct thrombin (factor IIa) inhibitors</li>
                <li>Parenteral and oral</li>
              </td>
              <td>
                <li>Alternatives to heparin</li>
                <li>Thromboembolism prevention/treatment</li>
              </td>
              <td>
                <ul>
                  <li>Directly inhibit thrombin (factor IIa).</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Bleeding</li>
                  <li>
                    limited reversal options (idarucizumab reverses dabigatran).
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Rivaroxaban</li>
                  <li>Apixaban</li>
                  <li>Edoxaban</li>
                </strong>
              </td>
              <td>
                <li>Direct acting anticoagulant</li>
                <li>Factor Xa Inhibitors</li>
                <li>Oral</li>
              </td>
              <td>
                Prevention/treatment of venous thromboembolism; stroke
                prevention in AF
              </td>
              <td>
                <ul>
                  <li>
                    Inhibit activated factor X → prevention of fibrinogen
                    activation
                  </li>
                  <li>Faster onset and shoter half life than warfarin</li>
                  <li>CYP450 dependent and independent metabolism</li>
                  <li>
                    Predictable pharmacokinetic and pharmacodynamic responses
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Bleeding</li>
                  <li>CYP interactions (inhibitors/inducers affect levels).</li>
                  <li>
                    Azole anti fungal angents and macrolide antibiotics can
                    inhibit CYP3A4 enzymes
                  </li>
                  <li><strong>Andexanet alfa</strong> reversal agent</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Streptokinase</li>
                  <li>Tissue Plasminogen Activator (tPa)</li>
                </strong>
              </td>
              <td>Thrombolytic / fibrinolytic</td>
              <td>
                Dissolve recent clots (PE, DVT, acute MI in some settings)
              </td>
              <td>Activates plasminogen → plasmin → fibrinolysis.</td>
              <td>Bleeding, including risk of major hemorrhage.</td>
            </tr>
            <tr>
              <td><strong>Aspirin (low dose)</strong></td>
              <td>Antiplatelet; COX‑1 / TXA2 inhibitor</td>
              <td>
                75-325mg for prophylaxis or prevention of clot formation and
                future CVS adverse events
              </td>
              <td>
                <ul>
                  <li>
                    Irreversibly inhibits COX‑1 → ↓ thromboxane A2 → ↓ platelet
                    aggregation
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>GI irritation</li>
                  <li>↑ bleeding risk</li>
                  <li>allergy</li>
                  <li>aspirin‑induced asthma</li>
                  <li>NSAIDs may enhance the antiplatelet effect of aspirin</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Clopidogrel</li>
                  <li>Prasugrel</li>
                </strong>
              </td>
              <td>
                <li>ADP (P2Y12) receptor inhibitors</li>
                <li>Oral prodrugs</li>
              </td>
              <td>Prevent thrombotic events (e.g., after MI, stents)</td>
              <td>
                <ul>
                  <li>
                    Prodrugs → active metabolite inhibits ADP binding to
                    platelets → inhibit aggregation and activiation
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Bleeding</li>
                  <li>Reduced effect in poor metabolizers (clopidogrel)</li>
                  <li>Altered taste reported in older women</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Abciximab</li>
                  <li>Tirofiban</li>
                </strong>
              </td>
              <td>Glycoprotein IIb/IIIa inhibitors</td>
              <td>
                IV use to prevent platelet aggregation in coronary interventions
              </td>
              <td>
                <ul>
                  <li>
                    Block GP IIb/IIIa receptor → prevent fibrinogen binding and
                    platelet aggregation.
                  </li>
                </ul>
              </td>
              <td>Bleeding (procedural/major).</td>
            </tr>
            <tr>
              <td><strong>Dipyridamole</strong></td>
              <td>Phosphodiesterase inhibitor / adenosine uptake inhibitor</td>
              <td>Adjunct for stroke prevention (often with aspirin)</td>
              <td>
                <ul>
                  <li>
                    Inhibits PDE → ↑ cAMP → vasodilation and ↓ platelet
                    activation (weak).
                  </li>
                </ul>
              </td>
              <td>Orthostatic hypotension</td>
            </tr>

            <tr>
              <td><strong>Vitamin K (phytonadione)</strong></td>
              <td>Clotting facilitator</td>
              <td>
                <li>Correct vitamin K deficiency</li>
                <li>
                  Often observed in patients with abnormalities in fat
                  absorption
                </li>
              </td>
              <td>-</td>
              <td>-</td>
            </tr>
            <tr>
              <td><strong>Tranexamic acid (Cyklokapron®)</strong></td>
              <td>
                <strong>Facilitates Clotting</strong>
                <li>Antiplasmin agent (antifibrinolytic)</li>
                <li>Oral tablet, oral rinse, IV</li>
              </td>
              <td>
                Reduce blood loss (hemophilia, post‑op bleeding), dental
                off‑label to control bleeding
              </td>
              <td>
                <ul>
                  <li>Inhibits conversion of plasminogen to plasmin</li>
                  <li>
                    increases collagen synthesis to strengthen fibrin clot.
                  </li>
                  <li>
                    Inhibit fibrinolysis by inhibiting plasminogen activation
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>-</li>
                  <li>PK: oral bioavailability ~45%, renally excreted 95%.</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Topical thrombin</strong></td>
              <td>Topical hemostatic agent</td>
              <td>Topical control of bleeding (surgical/dental)</td>
              <td>
                <ul>
                  <li>Converts fibrinogen to fibrin locally → hemostasis</li>
                  <li>must be applied topically only</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    Intravenous administration causes widespread clotting and
                    can be fatal
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Fibrin sealant (e.g., TISSEEL)</strong></td>
              <td>Topical fibrin glue / hemostatic sealant</td>
              <td>Surgical/dental hemostasis and wound adhesion</td>
              <td>
                <ul>
                  <li>
                    Two‑component system (thrombin + fibrinogen) → formation of
                    fibrin clot at application site.
                  </li>
                </ul>
              </td>
              <td>Adverse effects not detailed in deck.</td>
            </tr>
          </tbody>
        </table>
      </details>
      <br />
      <details>
        <summary>Lecture 9: GI Tract</summary>
        <table>
          <thead>
            <tr>
              <th><strong>Drug</strong></th>
              <th><strong>Class</strong></th>
              <th><strong>Main indication</strong></th>
              <th><strong>Mechanism of action</strong></th>
              <th><strong>Major adverse effects</strong></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>
                <strong>
                  <li>Cimetidine</li>
                  <li>Ranitidine</li>
                  <li>Famotidine</li>
                  <li>Nizatidine</li>
                </strong>
              </td>
              <td>H2 receptor antagonist</td>
              <td>
                <li>GERD</li>
                <li>PUD</li>
                <li>Reduce gastric acid</li>
              </td>
              <td>
                Competitive, reversible H2 receptor antagonist (blocks histamine
                stimulation of parietal cells).
              </td>
              <td>
                <ul>
                  <strong>Cimetidine</strong>
                  <li>May affect lidocaine metabolism</li>
                  <li>
                    Inhibits hepatic CYP enzymes → ↑ levels of diazepam,
                    warfarin, phenytoin
                  </li>
                  <li>Reduce dosage if taking diazepam</li>
                  <strong>Famotidine</strong>
                  <li>Taste disorder (rare)</li>
                  <li>Stevens–Johnson syndrome (rare)</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Omeprazole (strongest PPI)</li>
                  <li>Lansoprazole</li>
                  <li>Dexlansoprazole</li>
                  <li>Rabeprazole</li>
                </strong>
                <strong>
                  IV Medication:
                  <ul>
                    <li>Pantoprazole</li>
                    <li>Esomeprazole</li>
                  </ul>
                </strong>
              </td>
              <td>Proton pump inhibitor (PPI)</td>
              <td>
                <li>GERD</li>
                <li>PUD</li>
                <li>Part of H. pylori regimens</li>
              </td>
              <td>
                <li>
                  Oral forms are absorbed in inactive form → Travels to parietal
                  cells → acidic environment to activate
                </li>
                <li>
                  Prodrug activated in acidic canaliculus of parietal cells;
                  irreversibly inhibits H+/K+-ATPase (proton pump).
                </li>
              </td>
              <td>
                <ul>
                  <strong>All</strong>
                  <li>GI disturbance (nausea, abdominal pain, diarrhea)</li>
                  <li>
                    Prolonged acid suppression → ↓ absorption of iron, Ca, Mg,
                    B12
                  </li>
                  <li>
                    ↑ risk C. clostridioides difficile infections and pneumonia
                  </li>
                  <li>Osteoporosis</li>
                  <li>Xerostomia</li>
                  <li>
                    Clopidogrel (antiplatelet) should be taken with pantoprazole
                  </li>
                  <li>Long term effect may increase risk for MI</li>
                  <strong>Omeprazole</strong>
                  <li>Inhibitor of liver's cytochrome P450 enzymes</li>
                  <li>
                    May inhibit metabolism of diazepam, warfarin, phenytoin
                  </li>
                  <strong>Lansoprazole and Dexlansoprazole</strong>
                  <li>Nutrient malabsorption risk (long-term)</li>
                  <li>Infection risk with prolonged use</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Aluminum hydroxide</li>
                  <li>Magnesium Hydroxide (laxitive)</li>
                </strong>
              </td>
              <td>Antacid (weak base)</td>
              <td>
                <li>Symptomatic relief of heartburn/GERD</li>
                <li>
                  Not well absorbed in GI tract due to it binding to H<sup
                    >+</sup
                  >
                </li>
                <li>
                  Less effetive in ↑ pH of gastric acid vs H<sub>2</sub>
                  receptors antagonists and PPIs
                </li>
              </td>
              <td>Neutralizes gastric acid by binding H+ (weak base).</td>
              <td>
                <strong>All</strong>
                <ul>
                  <li>Hypokalemia</li>
                  <li>Changes gastric and urinary pH</li>
                  <li>Warfarin turns waste in acidic</li>
                  <li>Quinidine turns waste in basic</li>
                  <li>Impair absorption of tetracyclines and fluoroquinoles</li>
                  <li>Absorption of diazepam may be altered with antacids</li>
                  <li>milk causes chelation and increased gastric pH</li>
                </ul>
                <strong>Aluminum Hydroxide</strong>
                <ul>
                  <li>
                    Inhibits smooth muscle contraction in the GI Tract,
                    Constipation
                  </li>
                  <li>Hypophophatemia</li>
                  <li>Osteoporosis</li>
                  <li>Seizures</li>
                  <li>
                    Prevents GI absorption of ketoconazole and itraconazole by ↑
                    pH (administered 1 hour before taking this druge)
                  </li>
                </ul>
                <strong>Magnesium Hydroxide</strong>
                <ul>
                  <li>Diarrhea → Hypotension</li>
                  <li>Hypermagnesia</li>
                  <li>Hyporeflexia</li>
                  <li>Cardiac Arrest</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Calcium carbonate</li>
                  <li>Sodium bicarbonate</li>
                </strong>
              </td>
              <td>Antacid (systemically absorbed)</td>
              <td>Symptomatic relief of heartburn/GERD</td>
              <td>
                Neutralizes gastric acid (carbonate) and is systemically
                absorbed well.
              </td>
              <td>Said in Antacids above</td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Pilocarpine</li>
                  <li>Cevimeline</li>
                </strong>
              </td>
              <td>Sialagogue; muscarinic agonist</td>
              <td>
                Xerostomia (Sjogren’s, (radiation-induced dry mouth only for
                Pilocarpine))
              </td>
              <td>Enhance salivary sectrion through promoting PNS</td>
              <td>
                <li>Eye irritation (not recommended for ocular use)</li>
                <li><strong>Cevimeline</strong> has less adverse effects</li>
              </td>
            </tr>
            <tr>
              <td><strong>Atropine</strong></td>
              <td>Antimuscarinic (anti-sialagogue)</td>
              <td>
                <li>Reduce salivary/respiratory secretions pre-op</li>
                <li>Antispasmodic to relax GI tract</li>
                <li>
                  Inhibitory effects in bronchial tissue, salivary, sweat
                  glands, heart
                </li>
              </td>
              <td>
                Competitive muscarinic receptor antagonist (M1–M3) → ↓
                secretions, ↓ GI motility.
              </td>
              <td>Can completely prevent Ach action</td>
            </tr>
            <tr>
              <td><strong>Scopolamine</strong></td>
              <td>
                Antimuscarinic (anti-sialagogue / antiemetic for motion
                sickness)
              </td>
              <td>
                <li>Motion sickness</li>
                <li>Reduce secretions</li>
              </td>
              <td>
                Antimuscarinic with greater CNS penetration and longer duration
                than atropine.
              </td>
              <td>
                <ul>
                  <li>Sedation</li>
                  <li>Psychomotor impairment</li>
                  <li>Euphoria</li>
                  <li>Not preferred</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Metoclopramide</strong></td>
              <td>Antiemetic / prokinetic</td>
              <td>
                <li>Nausea/vomiting</li>
                <li>Gastroparesis</li>
              </td>
              <td>
                Dopamine (D2) receptor antagonist in CTZ; enhances GI motility
                (prokinetic).
              </td>
              <td>
                <ul>
                  <li>Extrapyramidal symptoms (EPS)</li>
                  <li>Tardive dyskinesia (with prolonged use)</li>
                  <li>Sedation</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Diphenoxylate</strong></td>
              <td>Antidiarrheal (opioid-like)</td>
              <td>Diarrhea</td>
              <td>
                Decreases intestinal motility via opioid receptor activity in
                gut.
              </td>
              <td>
                <ul>
                  <li>Constipation</li>
                  <li>Opioid-like adverse effects at high doses</li>
                  <li>Potential for abuse when combined with atropine</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Loperamide</strong></td>
              <td>Antidiarrheal (opioid)</td>
              <td>Diarrhea</td>
              <td>
                µ-opioid receptor agonist in gut → decreases motility (minimal
                CNS penetration at therapeutic doses).
              </td>
              <td>
                <ul>
                  <li>Constipation</li>
                  <li>Abdominal cramps</li>
                  <li>Rare cardiac effects in overdose</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Bismuth subsalicylate</strong></td>
              <td>Antidiarrheal / adsorbent</td>
              <td>-</td>
              <td>-</td>
              <td>
                <li>Tongue and stool darkening/black tongue (pigmentation)</li>
              </td>
            </tr>
            <tr>
              <td>
                <strong>Psyllium / Methylcellulose / Polycarbophil</strong>
              </td>
              <td>Bulk-forming laxatives</td>
              <td>Constipation</td>
              <td>
                Absorb water → increase stool bulk → stimulate peristalsis
                (fiber-based).
              </td>
              <td>
                <ul>
                  <li>Bloating</li>
                  <li>Gas</li>
                  <li>May obstruct if not taken with adequate water</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Magnesium salts (as laxatives)</strong></td>
              <td>Osmotic laxatives</td>
              <td>
                <li>Constipation</li>
                <li>Bowel prep</li>
              </td>
              <td>
                Poorly absorbed ions/osmotic agents draw water into lumen →
                stool softening/evacuation.
              </td>
              <td>
                <ul>
                  <li>Electrolyte disturbances</li>
                  <li>Dehydration</li>
                  <li>Cramping</li>
                  <li>Hypermagnesemia in renal impairment</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Lactulose / PEG</strong></td>
              <td>Osmotic laxatives</td>
              <td>
                <li>Constipation</li>
                <li>Hepatic encephalopathy (lactulose)</li>
              </td>
              <td>
                Osmotically retain water in colon → soften stool and increase
                motility.
              </td>
              <td>
                <ul>
                  <li>Bloating</li>
                  <li>Cramping</li>
                  <li>Electrolyte changes with overuse</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Bisacodyl / Senna / Castor oil</strong></td>
              <td>Stimulant (irritant) laxatives</td>
              <td>
                <li>Constipation</li>
                <li>Bowel prep</li>
              </td>
              <td>Stimulate enteric nerves → increased peristalsis.</td>
              <td>
                <ul>
                  <li>Abdominal cramping</li>
                  <li>Electrolyte imbalance with chronic use</li>
                  <li>Dependence/habitual use</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Docusate (stool softener)</strong></td>
              <td>Wetting agent / stool softener</td>
              <td>
                <li>Prevent/treat constipation</li>
                <li>Ease stool passage</li>
              </td>
              <td>
                Surfactant: reduces surface tension of stool → allows water/fat
                penetration → softens stool.
              </td>
              <td>
                <ul>
                  <li>Mild GI upset</li>
                  <li>Rarely electrolyte disturbance</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Methylnaltrexone / Alvimopan</strong></td>
              <td>Peripheral opioid receptor antagonists</td>
              <td>Opioid-induced constipation (selective GI µ antagonists)</td>
              <td>
                Block peripheral µ-opioid receptors in gut → restore motility
                without reversing central analgesia.
              </td>
              <td>
                <ul>
                  <li>Abdominal pain</li>
                  <li>Diarrhea</li>
                  <li>Potential GI adverse effects</li>
                </ul>
              </td>
            </tr>
          </tbody>
        </table>
      </details>
      <br />
      <details>
        <summary>Lecture 10: Antihyperglyemics</summary>
        <div class="blur-section">
          <b>Rapid Acting: </b>
          <span class="blur-target"> Lispro, Aspart, Inhaled </span>
        </div>
        <div class="blur-section">
          <b>Regular Acting: </b>
          <span class="blur-target"> Regular Insulin </span>
        </div>
        <div class="blur-section">
          <b>Intermediate-acting </b>
          <span class="blur-target"> NPH Insulin </span>
        </div>
        <div class="blur-section">
          <b>Long-acting: </b>
          <span class="blur-target"> Insulin Detemir </span>
        </div>
        <div>
          <b>Premixed Insulin: </b>
          <span class="blur-target"> 70/30 NPH/Reg </span>
        </div>
        <table>
          <thead>
            <tr>
              <th>Drug</th>
              <th>Class</th>
              <th>Main Indication</th>
              <th>Mechanism of Action</th>
              <th>Major Adverse Effects</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>Teplizumab</strong></td>
              <td>Prevention of Diabetes 1</td>
              <td>Indivudals with high risk for type 1 diabetes</td>
              <td>
                <li>
                  CD3 activates T cells and hence prevents β-cell distruction
                </li>
                <li>Antibodies directed against CD3</li>
              </td>
              <td><li>↓white cells, lymphocyte count</li></td>
            </tr>
            <tr>
              <td><strong>Metformin</strong></td>
              <td>Biguanide</td>
              <td>
                <ul>
                  <li>First‑line for type 2 diabetes</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Reduces hepatic gluconeogenesis &amp; lipogenesis</li>
                  <li>Slows intestinal sugar absorption</li>
                  <li>
                    Improves peripheral glucose uptake (glycolysis; minor)
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>GI upset (nausea, vomiting, diarrhea)</li>
                  <strong>
                    <li>Decreased vitamin B12 absorption</li>
                    <li>Risk of lactic acidosis in renal dysfunction</li>
                    <li>Generally no hypoglycemia or weight gain</li>
                  </strong>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Glipizide / Glyburide / Glimepiride</strong></td>
              <td>Sulfonylureas</td>
              <td>
                <ul>
                  <li>Type 2 diabetes when insulin secretagogue needed</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    Block β-cell K+/ATP channels → Ca2+ influx → insulin
                    secretion
                  </li>
                  <li>May also reduce hepatic gluconeogenesis</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Drug interactions (azole antifungals, macrolides)</li>
                  <li>Caution in hepatic/renal impairment</li>
                  <li>Corticosteroids may reduce efects</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Repaglinide</strong></td>
              <td>Meglitinide (non‑sulfonylurea secretagogue)</td>
              <td>
                <ul>
                  <li>Postprandial glucose control in type 2 diabetes</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    Stimulates <strong> rapid, short‑duration </strong>
                    insulin release (early postprandial) from β‑cells
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Hypoglycemia (lower risk than sulfonylureas)</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Pioglitazone</strong></td>
              <td>Thiazolidinedione (TZD)</td>
              <td>
                <ul>
                  <li>Type 2 diabetes (insulin sensitizer)</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    Acts on cell receptors → increases insulin sensitivity in
                    adipose tissue, liver, skeletal muscle → ↑glucose uptake
                  </li>
                  <li>Does not promote insulin release from the β-cell</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Weight gain</li>
                  <li>Fluid retention</li>
                  <li>Increased risk of heart failure/MI</li>
                  <li><strong> Liver toxicity </strong></li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Acarbose</strong></td>
              <td>Alpha‑glucosidase inhibitor</td>
              <td>
                <ul>
                  <li>Reduce postprandial hyperglycemia in type 2 diabetes</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    Inhibits intestinal α‑glucosidases → delays carbohydrate
                    digestion/absorption → lowers postprandial glucose
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Flatulence</li>
                  <li>Diarrhea</li>
                  <li>Abdominal pain</li>
                  <li>Does not cause hypoglycemia when used alone</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>Empagliflozin / Canagliflozin / Dapagliflozin</strong>
              </td>
              <td>SGLT2 inhibitors</td>
              <td>
                <ul>
                  <li>Type 2 diabetes</li>
                  <li>Reduce CV and kidney risk</li>
                  <li>Benefit in CHF/CKD</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    Inhibit SGLT2 in proximal renal tubule → reduce glucose
                    reabsorption → glycosuria → lower plasma glucose
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Genitourinary infections</li>
                  <li>Increased urinary frequency/urgency</li>
                  <li>Orthostatic hypotension</li>
                  <li>Low risk stress‑induced hypoglycemia</li>
                  <li>Contraindicated in renal insufficiency</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>
                  <li>Sitagliptin</li>
                  <li>Alogliptin</li>
                  <li>Linagliptin</li>
                  <li>Sitagliptin</li>
                  <li>Saxagliptin</li>
                </strong>
              </td>
              <td>DPP‑4 inhibitors</td>
              <td>
                <ul>
                  <li>Type 2 diabetes (augment incretin effect)</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    Inhibit DPP‑4 → ↑active GLP‑1 → enhanced glucose‑dependent
                    insulin secretion and reduced glucagon
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Rare oral mucosal ulcers</li>
                  <li>Pancreatitis reported</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Dulaglutide / Semaglutide</strong></td>
              <td>GLP‑1 receptor agonists</td>
              <td>
                <ul>
                  <li>Type 2 diabetes (improve glycemic control)</li>
                  <li>Assist weight loss</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    GLP‑1 Receptor agonist → insulin secretion response to meal,
                    ↓glucagon, ↓gastric emptying, ↑satiety
                  </li>
                  <li>Combined with other medications</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>GI symptoms (nausea, vomiting, decreased appetite)</li>
                  <li>Xerostomia</li>
                  <li>Halitosis</li>
                  <li>
                    Risk of pancreatitis and possible thyroid tumor signal
                  </li>
                  <li>
                    Delayed gastric emptying considerations causing aspiration
                  </li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Pramlintide</strong></td>
              <td>Amylin analogue</td>
              <td>
                <ul>
                  <li>Adjunct for type 1 and type 2 diabetes (with insulin)</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Synthetic amylin analogue → delays gastric emptying</li>
                  <li>Decreases glucagon secretion</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    Increased risk of severe hypoglycemia when combined with
                    insulin (boxed warning)
                  </li>
                  <li>Nausea/vomiting</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td><strong>Tirzepatide</strong></td>
              <td>Dual GIP &amp; GLP‑1 receptor agonist</td>
              <td>
                <ul>
                  <li>Type 2 diabetes</li>
                  <li>Weight management</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    Dual GIP + GLP‑1 agonist → stimulates insulin secretion,
                    improves glycemic control, increases satiety and lipolysis
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Similar to GLP‑1 RAs: GI adverse effects</li>
                  <li>Pancreatitis risk</li>
                  <li>Possible thyroid tumor signal</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td>
                <strong>Insulin (lispro/aspart/regular/NPH/detemir)</strong>
              </td>
              <td>Insulin (various formulations)</td>
              <td>
                <ul>
                  <li>Type 1 diabetes (required)</li>
                  <li>Type 2 when needed</li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>
                    Binds insulin receptor → IRS → PI3K/AKT → GLUT4
                    translocation → ↑cellular glucose uptake and glycogen
                    synthesis
                  </li>
                </ul>
              </td>
              <td>
                <ul>
                  <li>Hypoglycemia (most serious)</li>
                  <li>Hypokalemia (IV insulin)</li>
                  <li>Weight gain</li>
                  <li>Lipodystrophy at injection sites</li>
                  <li>Injection site irritation</li>
                  <li>
                    Inhaled insulin (Afrezza) can cause bronchospasm in chronic
                    lung disease
                  </li>
                </ul>
              </td>
            </tr>
          </tbody>
        </table>
      </details>
    </div>

    <style>
      /* same as before */
      .blurred {
        filter: blur(10px);
        transition: filter 0.3s ease;
      }

      /* Make clickable cursor for td */
      table td:not(:first-child) {
        cursor: pointer;
      }

      /* li inside blurred td will inherit blur from parent */
      table td.blurred li {
        filter: inherit;
      }

      .blur-buttons {
        text-align: center;
        margin-bottom: 16px;
      }
      .blur-buttons button {
        margin: 0 5px;
        padding: 5px 12px;
        font-size: 16px;
        cursor: pointer;
      }
      .blur-section li {
        cursor: pointer;
        margin-bottom: 6px;
      }

      /* Blur effect same as td */
      .blur-section li.blurred {
        filter: blur(10px);
        transition: filter 0.3s ease;
      }

      /* Override for bold text so it always stays clear */
      .blur-section li.blurred b {
        filter: none !important;
      }

      .blur-section .blur-target {
        cursor: pointer;
        display: inline-block;
      }

      .blurred {
        filter: blur(10px);
        transition: filter 0.3s ease;
      }
    </style>

    <script>
      // === BLUR LOGIC ===
      document.addEventListener("DOMContentLoaded", () => {
        // Select table cells + blur-target spans
        const blurCells = document.querySelectorAll(
          "table td:not(:first-child), .blur-section .blur-target",
        );

        blurCells.forEach((cell) => {
          cell.addEventListener("click", () => {
            cell.classList.toggle("blurred");
          });
        });

        // Keyboard shortcut (space toggles all)
        document.addEventListener("keydown", (event) => {
          if (event.code === "Space") {
            const allBlurred = Array.from(blurCells).every((cell) =>
              cell.classList.contains("blurred"),
            );
            if (allBlurred) {
              blurCells.forEach((cell) => cell.classList.remove("blurred"));
            } else {
              blurCells.forEach((cell) => cell.classList.add("blurred"));
            }
            event.preventDefault();
          }
        });

        // Buttons
        document.getElementById("blurAll").addEventListener("click", () => {
          blurCells.forEach((cell) => cell.classList.add("blurred"));
        });
        document.getElementById("unblurAll").addEventListener("click", () => {
          blurCells.forEach((cell) => cell.classList.remove("blurred"));
        });
      });

      // === CUSTOM HEADER ELEMENT ===
      class MyHeader extends HTMLElement {
        connectedCallback() {
          const text = this.innerHTML.trim() || "Section Title";

          this.innerHTML = `
        <div
          style="
            text-align: center;
            font-size: 24px;
            font-weight: bold;
            --tooltip-img-width: 400px;
          "
        >
          ${text}
        </div>
        <br />
      `;
        }
      }

      // Important: name must contain a hyphen
      customElements.define("my-header", MyHeader);

      function checkPassword() {
        const enteredPassword = document.getElementById("password").value;
        const correctPassword = "chud";
        if (enteredPassword === correctPassword) {
          document.getElementById("content").style.display = "block";
          document.querySelector("h2").style.display = "none";
          document.querySelector("p").style.display = "none";
          document.getElementById("password").style.display = "none";
          event.target.style.display = "none";
        } else {
          alert("Incorrect password. Please try again.");
        }
      }
    </script>
  </body>
</html>
